Korean J Intern Med.
1996 Jan;11(1):40-49.
Prognostic factors of patients with thymoma
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Abstract
OBJECTIVES
To analyze the prognostic factors influencing the survival of patients with thymoma, clinical characteristics, treatment modalities and survival of patients were evaluated. The efficacy of chemotherapy was also determined. METHODS: Retrospective study was done on one hundred patients whose diagnosis was confirmed pathologically at Seoul National University Hospital from 1981 to 1994. The staging was carried out according to the Masaoka system. Survival rate was calculated by the Kaplan-Meier method and prognostic factors were analyzed by a multivariate analysis (Weibull model). RESULTS: The stage of 100 patients was as follows: Stage I-50, II-6, III-27, IV A-10, IV B-7. The overall survival rates at 5 and 10 years after diagnosis were 73.1% and 58.7%, respectively. The 5-year survival differences, according to various prognostic factors, were as follows: 1) Stage: I-92.8%, II-100%, III-71.6%, IVA-25.9% and IVB-32.9% (p = 0.0029). 2) Age: < 60 years-79.5% and > or = 60 years-41.5% (p = 0.0489). 3) Extent of resection: Total patients: complete resection-87.6% and incomplete resection-50.5% (p > 0.05) Stage III: complete resection-66.7% and incomplete resection-75.5% (p > 0.05) 4) Myasthenia gravis: present-71.6% and absent-74.9% (p > 0.05) Seventeen patients were treated with a combination chemotherapy of Cyclophosphamide, Adriamycin and cisplatin(CAP). Two complete responses and seven partial responses (overall response rate of 53%) were observed with a median response duration of fourteen months. Combination chemotherapy with CAP was effective. CONCLUSIONS: Stage and age were the independent prognostic factors in patients with thymoma. However, the presence of myasthenia gravis or the extent of resection in stage III patients was not associated with the survival time.
MeSH Terms
-
Adolescent
Adult
Age Distribution
Aged
Combined Modality Therapy
Female
Human
Male
Middle Age
Myasthenia Gravis/etiology*
Myasthenia Gravis/mortality
Myasthenia Gravis/physiopathology
Myasthenia Gravis/therapy
Neoplasm Staging
Prognosis
Retrospective Studies
Survival Rate
Thymoma/diagnosis
Thymoma/mortality
Thymoma/physiopathology
Thymoma/therapy*
Thymus Neoplasms/diagnosis
Thymus Neoplasms/mortality
Thymus Neoplasms/physiopathology
Thymus Neoplasms/therapy*
